Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 3/20 | 0.67 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MAP2K3 | P46734 | 1/20 | 0.41 |
| ▸ | MAP2K6 | P52564 | 1/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.41 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.41 |
| ▸ | NEK10 | Q6ZWH5 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | PLAUR | Q03405 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL4846299 | 0.90 | GPR3 (0.54) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL29600756 | 0.82 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL51197 | 0.82 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL30897319 | 0.82 | GPR3 (1.00) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL4485428 | 0.76 | GPR3 (0.87) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL3630295 | 0.74 | ALDH1A1 (0.43) | GPR3LCKMAP2K3MAP2K6BTK | |
| Benzonaphthyridine SCHEMBL38660425 | 0.68 | GPR3 (0.70) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL7013453 | 0.68 | GPR3 (0.54) | GPR3LCKMAP2K3MAP2K6BTK | |
| SCHEMBL11517561 | 0.68 | GPR3 (0.61) | GPR3ALDH1A1SMN1; SMN2KMT2AMEN1 | |
| SCHEMBL38660517 | 0.68 | GPR3 (0.61) | GPR3ALDH1A1SMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| EP-3700534-A1 | METHODS OF TREATING PHELAN MCDERMID SYNDROME USING FARNESYL DIBENZODIAZEPINONES | Amo Pharma Ltd. (GB) | 2020-09-02 | — | — | EP | claimed |
| US-9974795-B2 | Anticancer agent composition | CARNA BIOSCIENCES, INC. (JP) | 2018-05-22 | — | — | US | claimed |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CARNA BIOSCIENCES, INC. (JP) | 2017-03-09 | — | — | US | claimed |
| EP-3100742-A1 | ANTICANCER AGENT COMPOSITION | Carna Biosciences Inc. (JP) | 2016-12-07 | — | — | EP | claimed |
| EP-2796112-B1 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2016-11-16 | — | — | EP | claimed |
| US-20100143332-A1 | COMBINATION THERAPY FOR PROLIFERATIVE DISORDERS | SCHERING CORPORATION | 2010-06-10 | — | — | US | claimed |
| EP-2086644-A2 | COMBINATION OF AN INHIBITOR OF DNA POLYMERASE-ALPHA AND AN INHIBITOR OF A CHECKPOINT KINASE FOR PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 2009-08-12 | — | — | EP | claimed |
| US-20090062255-A1 | TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO | THALLION PHARMACEUTICALS INC. (CA) | 2009-03-05 | — | — | US | claimed |
| WO-2008063558-A2 | COMBINATION OF AN INHIBITOR OF DNA POLYMERASE-ALPHA AND AN INHIBITOR OF A CHECKPOINT KINASE FOR PROLIFERATIVE DISORDERS | SCHERING CORPORATION (US) | 2008-05-29 | — | — | WO | claimed |
| WO-2007102936-A2 | POLYNUCLEOTIDES FOR PRODUCTION OF FARNESYL DIBENZODIAZEPINONES | THALLION PHARMACEUTICALS INC. (CA) | 2007-09-13 | — | — | WO | claimed |
| EP-0086980-B1 | SUBSTITUTED DIBENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THESE COMPOUNDS | Dr. Karl Thomae GmbH (DE) | 1986-01-02 | — | — | EP | claimed |
| EP-0085892-B1 | SUBSTITUTED BENZODIAZEPINONES, PROCESS FOR THEIR PREPARATION AND MEDICINES CONTAINING THEM | Dr. Karl Thomae GmbH (DE) | 1985-12-18 | — | — | EP | claimed |
| EP-0086980-A1 | Substituted dibenzodiazepinones, process for their preparation and medicines containing these compounds | Dr. Karl Thomae GmbH (DE) | 1983-08-31 | — | — | EP | claimed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | claimed |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | AMO PHARMA LTD. (GB) | 2026-04-14 | — | — | US | disclosed |
| EP-4698387-A1 | COMPOUND, RUBBER BLEND CONTAINING THE COMPOUND, VEHICLE TYRE COMPRISING THE RUBBER BLEND IN AT LEAST ONE COMPONENT, METHOD FOR PRODUCING THE COMPOUND, AND USE OF THE COMPOUND AS AN ANTI-AGING MEANS AND/OR ANTIOXIDANT AND/OR DYE | Continental Reifen Deutschland GmbH (DE) | 2026-02-25 | — | — | EP | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
| EP-0085892-A1 | Substituted benzodiazepinones, process for their preparation and medicines containing them | Dr. Karl Thomae GmbH (DE) | 1983-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062255-A1 | TUMOR-TARGETING EVALUATION METHODOLOGY AND COMPOUNDS RELATED THERETO | TSPO, MAPK1, MAPK3 | GPR3 338/4885LCK 775/4885MAP2K3 114/4885 |
| US-20170065609-A1 | ANTICANCER AGENT COMPOSITION | CDC7, CDC16, MCM7 | GPR3 4218/4885LCK 3016/4885MAP2K3 3136/4885 |
| US-12600703-B2 | Methods of synthesizing farnesyl dibenzodiazepinones | NR1H2, NR1H3, NR1H4 | GPR3 300/4885LCK 4674/4885MAP2K3 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.